Tarsus Pharma Files 8-K on Shareholder Vote Matters

Ticker: TARS · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1819790

Tarsus Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyTarsus Pharmaceuticals, Inc. (TARS)
Form Type8-K
Filed DateJun 18, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

TL;DR

Tarsus Pharma had a shareholder vote on June 12th, details to follow.

AI Summary

Tarsus Pharmaceuticals, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing indicates a corporate action or shareholder vote took place, but specific details of the vote, resolutions, or outcomes are not provided in this excerpt.

Why It Matters

This filing signals a significant corporate event involving shareholder decisions, which could impact the company's direction or governance.

Risk Assessment

Risk Level: medium — The filing indicates a shareholder vote, which can introduce uncertainty regarding corporate governance or strategic decisions.

Key Players & Entities

  • Tarsus Pharmaceuticals, Inc. (company) — Registrant
  • June 12, 2025 (date) — Date of earliest event reported
  • June 18, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • Irvine, CA (location) — Principal executive offices
  • (949) 418-1801 (phone_number) — Registrant's telephone number

FAQ

What specific matters were submitted to a vote of Tarsus Pharmaceuticals' security holders?

The provided excerpt of the 8-K filing does not specify the exact matters submitted to a vote of security holders; it only states that such matters were reported on.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on June 12, 2025.

What is the principal executive office address for Tarsus Pharmaceuticals, Inc.?

The principal executive office address for Tarsus Pharmaceuticals, Inc. is 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618.

What is the SIC code for Tarsus Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code for Tarsus Pharmaceuticals, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Under which section of the Securities Exchange Act of 1934 is this 8-K filed?

This 8-K filing is made pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding Tarsus Pharmaceuticals, Inc. (TARS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.